1. A 70-year-old female is referred to a medical oncology practice for the management of new lung metastases 12 months following a radical nephrectomy for clear cell renal carcinoma. She has a history of hypertension which is well-controlled with medication, mild anemia and mild chronic kidney disease from her prior nephrectomy. Based on the NCCN guidelines, what immunotherapy treatment options should be considered for this patient?

2. A 70-year-old male with high-grade NMIBC with urothelial carcinoma in-situ was treated with intravesical BCG, intravesical gemcitabine, and TURBT. His disease has persisted and he has declined radical cystectomy. Based on current NCCN guidelines, which immunotherapy agent(s) would be most appropriate to consider for this patient?

3. A 72-year-old male with stage IV prostate cancer that became resistant to androgen-deprivation treatment was initiated on enzalutamide. After 1 year, his disease became resistant to the enzalutamide. Genetic testing is negative for MSI-H/dMMR. Based on current NCCN guidelines, which is the most appropriate next treatment option for this patient?

4. Which of the following statements is CORRECT about the NCCN recommendations for an immune checkpoint inhibitor in urothelial carcinoma?

5. Which of the following is the only NCCN recommended immune checkpoint inhibitor regimen in the non-metastatic UC setting?

6. Most recently, the FDA approved avelumab for which of the following settings?

7. Which immune checkpoint inhibitor regimen is recommended by the NCCN for treatment of advanced MSI-H/dMMR prostate cancer?

8. George is a 72-year-old male who is being managed for a new lung metastasis 11 months following a radical nephrectomy for clear cell renal carcinoma. He has a history of hypertension which is well-controlled, and mild anemia and mild chronic kidney disease due to his prior nephrectomy. He will be receiving pembrolizumab plus axitinib. What patient education points should be discussed with George and his caregiver?

9. Which of the statements below describe adverse events with both VEGF targeted therapy and immunotherapy when they are used in combination?

10. Ellen is a 75-year-old woman being treated with a VEGF and an immune checkpoint inhibitor for renal cell cancer. She calls the oncology office to report that she is experiencing a Grade 2/3 adverse event, which is common to both the VEGF and immunotherapy. Which strategy is recommended to help determine the cause of her AEs?

« Return to Activity